Results 241 to 250 of about 197,589 (314)

Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges

The Chemical Record, EarlyView.
Cuproptosis is emerging as a distinct copper‐dependent cell death pathway, highlighting copper as a potential metabolic vulnerability in cancer. This review examines how coordination chemistry, redox regulation, and nanomaterial design shape Cu reactivity and therapeutic outcomes.
Chiara Ragusa, Valentina Oliveri
wiley   +1 more source

Case Report: response of HER2-positive ductal carcinoma <i>in situ</i> to osimertinib with supporting <i>in vitro</i> evidence. [PDF]

Front Oncol
Baba S, Koketsu M, Kuroda H, Suzuki M, Nishihara H, Kato Y, Kawami H, Harada O.   +7 more
europepmc   +1 more source

Recent Advances in Photocatalyst‐Driven Protein Labeling and Proximity Mapping

The Chemical Record, EarlyView.
Photocatalyst‐driven protein labeling and proximity mapping have rapidly advanced as powerful strategies for spatiotemporal control in complex biological environments. This review integrates recent developments across single‐electron transfer and energy transfer‐based mechanisms and highlights how catalyst design, reactive intermediates, and diffusion ...
Shinichi Sato, Kazuki Miura, Juki Nakao, Hiroyuki Nakamura   +3 more
wiley   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies. [PDF]

Clin Cancer Res
Lee KW, Elimova E, Oh DY, Beeram M, Doi T, Yeung KT, Samuel Nached T, Shah KV, Fuller DS, Shpektor D, Loro E, Meric-Bernstam F.   +11 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer. [PDF]

ESMO Open
Lee CK, Seo DH, Park S, Yuh T, Kim Y, Park H, Shim JS, Kim H, Kim HS, Jung M, Chung HC, Rha SY.   +11 more
europepmc   +1 more source